Clinical experience of MEK inhibitors in cancer therapy.
Finding new therapies to assist in the treatment of cancer is a major challenge of clinical research. Small molecules that inhibit different molecular targets at the different levels of the MAPK pathway have been developed. Several MEK inhibitors have been examined in early-phase clinical trials and the current state of clinical results using these therapies is presented here.
Wang
Ding
D
Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University, 4th Floor HWCRC, 4100 John R, Detroit, MI 48201, USA.
Boerner
Scott A
SA
Winkler
James D
JD
LoRusso
Patricia M
PM
D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D011905:Genes, ras; D006801:Humans; D020935:MAP Kinase Signaling System; D020929:Mitogen-Activated Protein Kinase Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics
D047428:Protein Kinase Inhibitors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020929:Mitogen-Activated Protein Kinase Kinases